Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis
Authors' conclusion
This study highlights the differential cardiovascular effectiveness and safety profiles of hypoglycemic therapies in real-world settings, providing valuable insights for optimizing T2D management, particularly in patients with comorbid hypertension.
Study context
- Population
- Patients with T2D and hypertension who initiated metformin as first-line therapy
- Exposure
- Glucose-lowering drug classes added to metformin, compared pairwise
- Outcome
- 3-point MACE
Methodological detailselectronic health records from two databases, propensity score matching, Cox proportional hazards models
- Electronic health records from two databases
- Propensity score matching
- Cox proportional hazards models
Main finding
As reported in the abstract
Hazard ratio (CI)
GLP-1 RAsvs Insulin
0.48(0.31–0.76)
DPP4isvs Insulin
0.70(0.57–0.85)
Glinidesvs Insulin
0.70(0.52–0.94)
SUsvs DPP4is
1.30(1.06–1.59)
DPP4isvs Acarbose
0.62(0.51–0.76)
GLP-1 RAsvs Acarbose
0.47(0.29–0.75)
Glinidesvs Acarbose
0.59(0.43–0.81)
Observational data: associations, not effects.
Further findings
- Similar patterns were observed for 4-point major adverse cardiovascular events (MACE)
Safety
Safety outcomes
- DPP4is associated with reduced risk of CKD
- Insulin associated with reduced risks of inflammatory polyarthritis and insomnia
- DPP4is associated with higher risks of coronary atherosclerotic diseases and hypertensive heart disease
Original publication
Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis. Cardiovasc Diabetol. Published 20 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →